drugset / Trial / NCT05317325
A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCC
NaSingle-groupOpen-labelTreatment
Summary
The aim of this single center, single arm and prospective study is to explore the safety and efficacy of tumor antigen-pulsed DC vaccine( OCDC and NeoDC) for postoperative adjuvant treatment of ESCC
Timeline
- Start
- 2022-04-01
- Primary completion
- 2023-12-30
- Completion
- 2024-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NeoDC | Unknown | — | Subcutaneous |
| Subject | OCDC | Unknown | — | Subcutaneous |